Physician

Habib Mohammad-Hussein Ghaddar, M.D.

According to 2025 Medicare claims, Habib Ghaddar, M.D. (NPI: 1043259476) practices hematology/oncology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78596-6608.

Ghaddar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 321 traditional Medicare patients, billed 58,063 HCPCS/CPT codes, and received $889,851 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,450 prescription claims across 290 beneficiaries totaling $3,206,016 in drug costs, led by Revlimid (Lenalidomide). DME data shows 18 claims. Open Payments data shows 31 records totaling $29,102. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,345,446 to $3,206,016. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	689	100,207	$1,508,124
2016	678	81,725	$1,418,339
2017	685	101,417	$1,737,742
2018	664	93,784	$1,750,970
2019	613	92,942	$1,738,981
2020	565	119,329	$2,220,203
2021	480	90,646	$1,689,175
2022	434	91,785	$1,812,845
2023	415	92,979	$1,673,593
2024	321	58,063	$889,851

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	230	1,248	$1,345,446
2016	218	1,256	$1,321,065
2017	219	1,258	$1,686,137
2018	242	1,385	$2,590,531
2019	248	1,293	$3,175,868
2020	278	1,524	$3,654,297
2021	269	1,318	$2,859,000
2022	292	1,427	$3,051,757
2023	284	1,333	$2,207,458
2024	290	1,450	$3,206,016

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	50	124	$40,203
2016	44	91	$21,797
2017	56	77	$11,902
2018	46	93	$13,772
2019	38	91	$10,613
2020	20	30	$2,957
2021	27	37	$5,291
2022	27	41	$7,091
2023	15	20	$2,352
2024	11	18	$2,033

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	93	194	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	173	239	$55
80053	Blood test, comprehensive group of blood chemicals	195	503	$10
36415	Insertion of needle into vein for collection of blood sample	211	538	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	225	618	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	26	700	$435,557
Calquence	Acalabrutinib Maleate	22	660	$341,432
Promacta	Eltrombopag Olamine	22	660	$281,967
Alecensa	Alectinib Hcl	17	510	$278,894
Tagrisso	Osimertinib Mesylate	12	360	$202,112

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	18	$2,033

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$261	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	19	$28,841	Daiichi Sankyo Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Habib Mohammad-Hussein Ghaddar, M.D.?

Tedicare shows public-source Medicare data for Habib Mohammad-Hussein Ghaddar, M.D. (NPI 1043259476), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Habib Mohammad-Hussein Ghaddar, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Habib Mohammad-Hussein Ghaddar, M.D.?

Habib Mohammad-Hussein Ghaddar, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Habib Mohammad-Hussein Ghaddar, M.D. have Open Payments data?

Habib Mohammad-Hussein Ghaddar, M.D. has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.